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Management of cryptoccocal meningitis in resource-limited 
settings: A systematic review
Derek Sloan, Sipho Dlamini, Martin Dedicoat
To the Editor: Cryptococcal meningitis (CM) remains a 
serious cause of mortality and morbidity in individuals 
infected with the human immunodeficiency virus (HIV). 
The optimal treatment of CM is unknown. We conducted a 
systematic review to determine the best treatment for CM with 
an emphasis on resource-poor settings. Six studies met the 
inclusion criteria; none was found that compared amphotericin 
B with fluconazole. From the available evidence, it is not 
possible to determine which treatment is superior for CM.
Background
Despite the increasingly wide availability of antiretroviral 
therapy (ART), CM remains a significant cause of mortality 
and morbidity among HIV-infected individuals; untreated, 
its outcome is universally fatal.1 In South Africa, despite 
the availability in the public sector of antifungal therapy 
(fluconazole (FLU) and amphotericin B (AmB)) for treating 
CM, inpatient mortality is around 25%.2 The ideal management 
of CM remains unclear. Many patients with HIV infection 
who present for the first time to health services with a major 
opportunistic infection such as CM are unaware of their status. 
We aimed to assess the evidence for which antifungal regimen 
and other management to use, emphasising resource-poor 
settings, for treating CM in HIV-infected individuals to enable 
them to survive and benefit from ART.
Methods
Relevant studies were identified using the Cochrane 
HIV/AIDS group search strategy from databases from 
January 1980 to June 2008. Key search words included 
meningitis, Cryptococcus neoformans, treatment, trial, human 
immunodeficiency virus, acquired immunodeficiency 
syndrome, antifungal agents, AmB, flucytosine (FLC), FLU, 
azole, lumbar puncture, cerebrospinal fluid (CSF) pressure and 
acetazolamide. Trials deemed suitable were randomised trials 
of HIV-infected adults with a first episode of CM diagnosed 
on CSF examination, by India ink staining, CSF culture or 
cryptococcal antigen testing. The authors extracted data using 
standardised forms and performed analysis using Rev Man 
4.2.7 software.
Results
Six studies are included in the review;3-8 5 compared antifungal 
treatments.4-8 One study that addressed lowering intracranial 
pressure using oral acetazolamide to lower intracranial 
pressures was stopped early because of excessive metabolic 
acidosis3 (Table I). No study demonstrated differences in 
survival between groups.
Conclusions
We aimed to determine the best treatment for CM in resource-
limited settings in which only AmB and FLU were usually 
available. No suitable studies comparing these two drugs 
were found; therefore, we cannot recommend either treatment 
as superior to the other. Although AmB-containing regimens 
have caused more rapid sterilisation of CSF compared with 
FLU,9 we found no evidence of improved survival. The optimal 
dosing and duration of AmB remains unclear; the Southern 
African HIV Clinicans Society recommended dose is 1 mg/kg 
daily for 14 days, followed by FLU 400 mg daily for 8 weeks, 
then FLU 200 mg daily for life; if AmB is not available or its 
use is contraindicated, then FLU should be used as first-line 
treatment.10
Liposomal AmB is associated with less adverse events than 
AmB and may be useful in selected patients where resources 
allow.
FLC (not available in South Africa) in combination with AmB 
leads to faster and increased sterilisation of CSF compared 
with using AmB alone. This finding does not correlate with 
improved clinical outcomes. Infectious Diseases Society 
of America guidelines recommend that AmB be given in 
combination with FLC.11
Future research into the management of CM in resource-
limited settings should focus on the most effective use of 
medications available in these settings as well as other 
management modalities such as control of intracranial 
pressure. The other major issue is the optimal timing of 
initiation of ART either during or after initial treatment of 
CM, with the aim of maximising early immunological benefit 
and reducing the incidence of immune reconstitution-related 
complications.
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Table I. Summary of included studies
Interventions  Study (reference)     Results
Acetzolamide   Newton et al.3  Study terminated early owing to excess deaths 2/12 v. 0/10 relative
v. placebo      risk (RR) 4.23 95% confidence interval (95% CI) 0.23 - 79.1 and FLU v. 
      excess acidosis 5/12 v. 0/10 RR 9.31 95% CI 0.58 - 150.25 in the   
      intervention group.
FLU v. FLU  Mayanja-Kizza et al.4 The dose of FLU used (200 mg daily) was lower than the currently 
and FLC      recommended 400 mg daily. FLC was given at a dose of 150 mg/kg
      daily. There was no difference in death rate at 2 weeks: 4/25 v. 10/25 RR  
      0.4 95% CI 0.14 - 1.11 or at 6 months: 17/25 v. 22/25 RR 0.77 95% CI 0.57 - 
       1.05; there was no difference in number of patients with sterile CSF at 2  
      months after treatment: 4/8 v. 12/15 RR 0.4 95% CI 0.11 - 1.36. No major  
      adverse events occurred in either group.
AmB v. AmB   Brouwer et al.5 and   AmB 0.7 mg/kg daily was compared with AmB 0.7 mg/kg/day 
and FLC   van der Horst et al.6  with FLC 100 mg/kg/day. The studies were analysed together for the   
      outcomes of death at 14 days and sterility of CSF culture at 14 days.   
      There was no difference in the proportion of deaths at 14 days: 12/195  
      v. 12/217 RR 1.1 95% CI 0.51 - 2.4, but there was higher proportion of 
      patients with sterile CSF cultures at 14 days in the group of patients   
      receiving FLC: 93/195 v. 128/217 RR 0.81 95% CI 0.68 - 0.98. There was  
      no difference in major adverse events between the two treatment arms:  
      5/195 v. 6/217 RR 0.94 95% CI 0.29 - 3.03.
      Brouwer et al.5 recorded deaths at 10 weeks; there was no difference   
      between the two groups: 3/16 v. 1/16 RR 2.81 95% CI 0.33 - 24.16.
      Van der Horst et al.6 found no difference in symptomatic improvement  
      at 14 days between the two groups: 149/179 v. 157/202 RR 1.07 95% CI  
      0.97 - 1.18.
AmB v. AmB,   Brouwer et al.5  AmB was compared with AmB, FLC and FLU. AmB 0.7 mg/kg 
FLC and FLU     daily was given, FLC 100 mg/kg daily and FLU 400 mg daily.
      There was no significant difference in the proportion of patients
      dying at 2 or 10 weeks: 2/16 v. 1/16 RR 2.0 95% CI 0.2 - 19.91 and 3/16 
      v. 3/16 RR 1.0 95% CI 0.24 - 4.23. There was no difference in the   
      proportion of patients with sterile CSF at 14 days: 2/16 v. 4/16 RR 0.5   
      95% CI 0.11 - 2.35. Neither group had serious adverse events.
AmB and FLC   Brouwer et al.5  AmB and FLC were compared with AmB, FLC and FLU. There was
v. AmB, FLC and FLU    no difference in death at 14 days or 10 weeks between the groups: 
      1/15 v. 1/16 RR 1.07 95% CI 0.07 - 15.57 and 1/15 v. 3/16 RR 1.07 95%  
      CI 0.07 - 15.57. There was no difference in the proportion of patients with  
      sterile CSF at 14 days: 6/15 v. 4/16 RR 1.6 95% CI 0.56 - 4.58. There were  
      no serious adverse events in either group.
AmB and FLC   Brouwer et al.5  AmB and FLC were compared with AmB and FLU. There was no   
v. AmB and FLU     difference in the proportion of deaths at 14 days or 10 weeks: 1/15 v.   
      5/16 RR 0.21 95% CI 0.03 - 1.62 and 1/15 v. 7/16 RR 0.15 95% CI 0.02 -  
      1.1. There was no difference in the amount of patients with sterile CSF  
      at 14 days: 6/15 v. 3/16 RR 2.13 95% CI 0.65 - 7.04. There were no serious  
      adverse events in either group.
AmB v. AmB and FLU Brouwer et al.5  AmB was compared with AmB and FLU. There was no difference  
      in the proportion of deaths at 14 days or 10 weeks: 2/16 v. 5/16 RR 0.4  
      95% CI 0.09 - 1.77 and 3/16 v. 7/16 RR 0.43 95% CI 0.13 - 1.37. Also, there  
      was no difference in the number of patients with sterile CSF at 14 days:  
      2/16 v. 3/16 RR 0.67 95% CI 0.13 - 3.47. There were no serious adverse  
      events in either group.
AmB and FLU v. AmB,  Brouwer et al.5  AmB and FLU were compared with AmB, FLC and FLU. There was no 
FLU and FLC     difference in the proportion of deaths at 14 days or 10 weeks: 5/16 v. 1/16  
      RR 5.0 95% CI 0.66 - 38.15 and 7/16 v. 3/16 RR 2.33 95% CI 0.73 - 7.45. Also,  
      there was no difference in the number of patients with sterile CSF at 14 days:  
      3/16 v. 4/16 RR 0.75 95% CI 0.2 - 2.83. There were no serious adverse events  
      in either group.
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A full version of this review is available in the Cochrane 
database.12
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Table I. Summary of included studies - continued
Standard-dose AmB  Bicanic et al.7  AmB 0.7 mg/kg and FLC 0.25 mg/kg for 2 weeks was compared
and FLC v. high-     with AmB 1 mg/kg with FLC 0.25 mg/kg for 2 weeks. There was
dose AmB and FLC     no difference in the proportion of deaths at 14 days or 10 weeks: 1/30 v.  
      3/34 RR 0.34 95% CI 0.04 - 3.44 and 6/30 v. 9/34 RR 0.76 95% CI 0.03 - 1.83.  
      The proportion of patients with sterile CSF at 14 days was not different  
      between the two treatment groups: 6/29 v. 7/28 RR 1.13 95% CI 0.43 - 2.94.  
      There was no major difference in major adverse events defined as side-effects  
      of treatment leading to the study interventions being terminated: 1/30 v. 5/34 
      RR 0.23 95% CI 0.03 - 1.83.
AmB v. liposomal AmB Leenders et al.8  AmB 0.7 mg/kg daily for 21 days was compared with liposomal AmB 4 mg/ 
      kg daily for 21 days. There was no difference in the proportion of patients  
      who had a clinical response after 3 weeks’ treatment: 12/15 in the liposomal  
      AmB group v. 11/13 in the AmB group RR 0.95 95% CI 0.67 - 1.33. There was  
      no difference in the proportion of deaths at 14 days, 10 weeks or 6 months. At 
      6 months, 2/15 patients who received liposomal AmB had died and 1/13  
      patients who received AmB: RR 1.73 95% CI 0.12 - 59.4.
      Major adverse events were less common in patients who received   
      liposomal AmB: 2/15 v. 9/13 RR 0.19 95% CI 0.05 - 0.74.
      There was no statistically significant difference in the proportion of   
      patients with sterile CSF at 14 days in either group but the trend   
      suggests that liposomal AmB was superior, with 10/15 patients having  
      sterile CSF v. 1/9 in the AmB group RR 6.0 95% CI 0.91 - 39.41.
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